Viridian Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing potential best-in-class medicines for patients with serious and rare diseases. The ... Viridian Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing potential best-in-class medicines for patients with serious and rare diseases. The company specializes in antibody discovery and protein engineering to create differentiated therapeutic candidates targeting previously validated drug targets in established disease areas. Viridian is primarily focused on therapies for thyroid eye disease (TED), advancing multiple clinical candidates including veligrotug (VRDN-001) and VRDN-003, both undergoing pivotal phase 3 trials worldwide. Beyond TED, Viridian is developing a portfolio of neonatal Fc receptor (FcRn) inhibitors aimed at treating multiple autoimmune diseases. The company strives to improve treatment options by offering therapies that are safe, effective, and easy to use for people affected by autoimmune and rare diseases. Viridian maintains a strong financial position to support its clinical programs and commercial preparations, highlighting its significant role in the biopharmaceutical market addressing unmet medical needs in rare and autoimmune conditions.
Pending data availability
Climate Targets Data missing for Viridien
We haven’t collected Climate Targets data for Viridien yet, or the company
hasn’t made it publicly available.